

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/061,128
				Filing Date	January 30, 2002
				First Named Inventor	Schinazi, et al.
				Group Art Unit	1637
				Examiner Name	Jezia Riley
Sheet	1	of	2	Attorney Docket Number	18085.105232 EMU 2000 CIP

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
<i>M</i>	AA	6,458,773	B1	GOSELIN, et al.	10-01-2002	
	<del>AB</del>	<del>6,407,077</del>	<del>B1</del>	<del>GOSELIN, et al.</del>	<del>06-18-2002</del>	<i>Duplicate</i>
	<del>AC</del>	<del>6,232,300</del>	<del>B1</del>	<del>SCHINAZI, et al.</del>	<del>05-15-2001</del>	<i>Duplicate</i>
<i>M</i>	AD	6,147,058		YOSHIMURA, et al.	11-14-2000	
<i>M</i>	AE	6,103,707		YAMADA, et al.	08-15-2000	
<i>M</i>	AF	5,817,799		MARQUEZ, et al.	10-06-1998	
<i>M</i>	AG	5,808,040		CHU, et al.	09-15-1998	
<i>M</i>	AH	5,210,085		LIOTTA, et al.	05-11-1993	
<i>M</i>	AI	4,908,440		STERZYCKI, et al.	03-13-1990	
<i>M</i>	AJ	4,000,137		DVONCH, et al.	12-28-1976	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number	Kind Code (if known)				
<i>M</i>	AK	EP	0,839,813	A1	Yamasa Corp.	05-06-1998		
<i>M</i>	AL	EP	0,463,470	A2	Hoffman-LaRoche	01/02/1992		
<i>M</i>	AM	EP	0,357,571	B1	Medivir Aktiebolag	04-03-1996		
<i>M</i>	AN	EP	0,292,023	A2	Hoffman-LaRoche	05-24-1988		
<i>M</i>	AO	WO	95/20595	A1	Univ. of Georgia Res. Found., & Yale Univ.	08/03/1995		
<i>M</i>	AP	WO	94/14831	A1	Univ. of Alberta	07-07-1994		
<i>M</i>	AQ	WO	92/08727	A1	Consig. Naz. Ricerche	05-29-1992		
<i>M</i>	AR	WO	91/11186	A1	Emory University	08-08-1991		
<i>M</i>	AS	WO	88/08001	A1	Aktiebolaget Astra	10-20-1988		

Examiner Signature	<i>[Signature]</i>	Date Considered	2/17/04
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP t-09. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB-08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A-PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/061,128
Filing Date	January 30, 2002
First Named Inventor	Schinazi, et al.
Group Art Unit	1637
Examiner Name	Jezia Riley
Attorney Docket Number	18085.105232 EMU 2000 CIP

Sheet 2 of 2

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
MA	BA	BOUFFARD, D.Y., et al., "Kinetic Studies of 2',2'-difluorodeoxycytidine (Gemcitabine) with Purified Human Deoxycytidine Kinase and Cytidine Deaminase," <i>Biochemical Pharmacology</i> , 45(9):1857-1861 (1993).	
MA	BB	JEONG, L.S., et al., "Unanticipated Retention of Configuration in the DAST Fluorination of Deoxy-4'-thiopyrimidine Nucleosides with 'Up' Hydroxyl Groups," <i>Tetrahedron Letters</i> , 35(41):7569-7572 (1994).	
MA	BC	JEONG, L.S., et al., "Facile Fluorination of Deoxy-4'-thiopyrimidine Nucleosides with 'Down' Hydroxyl Groups. Retention of Configuration After Fluoride Opening of the Quaternized N <sup>3</sup> -MEM Anhydronucleosides," <i>Tetrahedron Letters</i> , 35(41):7573-7576 (1994).	
MA	BD	MONTGOMERY, J.A., et al., "9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)guanine: A Metabolically Stable Cytotoxic Analogue of 2'-Deoxyguanosine," <i>J. Med. Chem.</i> , 29(11):2389-2392 (Nov. 1986).	
MA	BE	NIHATA, S., et al., "Synthesis of 2-Fluoro Sugar and Its Condensation Reaction with Silylated Thymine," <i>Bull. Chem. Soc. Jpn.</i> , 68(5):1509-1512 (May 1995).	
MA	BF	OKABE, M., et al., "Synthesis of 1-(2,3-Dideoxy-2-fluoro-β-D-threo-pentofuranosyl)cytosine (F-ddC). A Promising Agent for the Treatment of Acquired Immune Deficiency Syndrome," <i>J. Org. Chem.</i> , 56:4392-4397 (Feb. 1991).	
MA	BG	VAN AERSCHOT, A., et al., "3'-Fluoro-2',3'-dideoxy-5-chlorouridine: Most Selective Anti-HIV-1 Agent among a Series of New 2'- and 3'-Fluorinated 2',3'-Dideoxynucleoside Analogues," <i>J. Med. Chem.</i> , 32(8):1743-1749 (August 1989).	

Examiner  
Signature

*[Handwritten Signature]*

Date  
Considered

7/17/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Patent type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### Complete if Known

Application Number	10/061,128
Filing Date	January 30, 2002
First Named Inventor	Schinazi, et al.
Group Art Unit	1637
Examiner Name	
Attorney Docket Number	18085.105232 (EMU2000CIPCON)

Sheet	1	1
-------	---	---

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
<i>MS</i>	AA	SCHINAZI, et al., "Selective Inhibition of Human Immunodeficiency viruses by Racemates and Enantiomers of cis-5-Fluoro-1-2[Hydroxymethyl]-1, 3-Oxathiolane-5-yl]Cytosine" <i>Antimicrobial Agents and Chemotherapy</i> , November 1992, pp. 2423-2431.	
<i>MS</i>	AB	MARQUEZ, V.E., et al., <i>Nucleosides &amp; Nucleotides</i> , 14(3-5), 555-558 (1995)	
<i>MS</i>	AC	SIDDIQUI MA et al., <i>Tetrahed. Letters</i> , vol. 39 no. 13 26 March 1998.	
<i>MS</i>	AD	WANTANABE, et al., "Synthesis and Anti-HIV Activity of 2'-"Up"-Fluoro Analogues of Active Anti-Aids Nucleosides 3'- Azido-3'deoxythymidine (AZT) and 2', 3'- dideoxycytidine (DDC)," <i>J. Med. Chem.</i> 1990, 33, 2145-2150.	

Examiner Signature	<i>Per Li</i>	Date Considered	2/17/04
--------------------	---------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.